← All stories
Markets
STAT+: The promise of radiopharmaceuticals smacks into safety concerns
Despite excitement over the potential of radiopharmaceuticals as cancer treatments, drug developers are hitting new hurdles.
Covered by 1 outlet
All coverage · 1 article